Loading
A phase 2 trial of Temozolomide in glioma & glioblastoma, run by BPGbio, active and no longer recruiting.
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) is a phase 2 interventional study registered as NCT04752813 by BPGbio, with 50 participants enrolled, started 2022-08-22 and due to reach its primary completion in 2026-08-25. Interventions recorded: BPM31510, Temozolomide (TMZ) and Radiation.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/